Payment overview · 2025
General Payments
$91.56
5 reported records · 4 companies
Healthcare provider profile · identity verified
Patrick O'Hara
Allopathic & Osteopathic Physicians|Family Medicine · FREDERICKTOWN, MO · NPI 1508972233
Verified facts
What the public records show
CMS Open Payments records show Patrick O'Hara received $91.56 in general payments during 2025 across 5 reported records.
Edwards Lifesciences Corporation accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $41.65 | 45.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.21 | 21.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.13 | 18.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.57 | 14.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.56 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 309 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 49 |
| Omeprazole | Omeprazole | 239 | 46 |
| Metformin Hcl | Metformin Hcl | 238 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 237 | 49 |
| Lisinopril | Lisinopril | 235 | 46 |
| Alprazolam | Alprazolam | 190 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 26 |
| Eliquis | Apixaban | 156 | 17 |
| Furosemide | Furosemide | 150 | 25 |
| Tramadol Hcl | Tramadol Hcl | 150 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 23 |
| Potassium Chloride | Potassium Chloride | 139 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 131 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 31 |
| Pregabalin | Pregabalin | 125 | 18 |
| Famotidine | Famotidine | 118 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 18 |
| Carvedilol | Carvedilol | 104 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 16 |
| Meloxicam | Meloxicam | 92 | 18 |
| Montelukast Sodium | Montelukast Sodium | 90 | 15 |
| Celecoxib | Celecoxib | 87 | 15 |
| Trazodone Hcl | Trazodone Hcl | 83 | 14 |
| Lorazepam | Lorazepam | 82 | 16 |
| Jardiance | Empagliflozin | 81 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 25 |
| Losartan Potassium | Losartan Potassium | 70 | 18 |
| Clonazepam | Clonazepam | 68 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 68 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Allopurinol | Allopurinol | 60 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 16 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Prednisone | Prednisone | 51 | 23 |
| Baclofen | Baclofen | 49 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 49 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 42 | 42 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 38 | 38 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 12 |
| Azithromycin | Azithromycin | 33 | 26 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Lubiprostone | Lubiprostone | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Fentanyl | Fentanyl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 18 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Dutasteride | Dutasteride | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.56 · 5 records | Edwards Lifesciences Corporation | NURTEC ODT, SPRAVATO, VRAYLAR, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error